Renal Impact of KAFTRIO in Mucoviscidose Population (IRT-MUCO)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Etienne NOVEL CATIN
- Phone Number: +33 04.72.67.87.37
- Email: etienne.novel-catin@chu-lyon.fr
Study Locations
-
-
-
Pierre-Bénite, France, 69310
- Recruiting
- Centre Hospitalier LYON SUD
-
Contact:
- Etienne NOVEL-CATIN, MD
- Phone Number: 04.72.67.87.37
- Email: etienne.novel-catin@chu-lyon.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient with cystic fibrosis
- More than 18 years old
- Eligible for KAFTRIO
Exclusion Criteria:
- KAFTRIO contraindication
- Patient less than 18 years old
- Dialysis patient
- Pregnant woman
- Greffed patient
- Patient opposition to data collection
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patient with cystic fibrosis, eligible for KAFTRIO therapy
Patient with cystic fibrosis, eligible for KATRIO, over 18 years old.
|
Collection of Uricuria, phosphaturie, calciuria, magnesuria, glycosuria, citraturia, oxaluria, before and after initiation of KAFTRIO
Arterial pressure, glycemia, glycated hemoglobin, lipid profile, weight, serum and urinary electrolytes, hepatic check, complete blood count, calcium phosphate balance and urinary sediment analysis before and after initiation of KAFTRIO
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modification of the parameters of the lithiasis assessment
Time Frame: 1 month after initiation of KAFTRIO
|
Change in blood phosphorus and calcium metabolism ; Change in calciuria mmol/d ;Change in urinary pH, urinary specific gravity (g/mL) and crystalluria
|
1 month after initiation of KAFTRIO
|
|
Modification of the parameters of the lithiasis assessment
Time Frame: 7 months after initiation of KAFTRIO
|
Change in blood phosphorus and calcium metabolism ; Change in calciuria mmol/d ;Change in urinary pH, urinary specific gravity (g/mL) and crystalluria
|
7 months after initiation of KAFTRIO
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in volemic parameter
Time Frame: 1 month after initiation of KAFTRIO
|
body mass index (BMI) (kg/m²), systolic and diastolic blood pressure (mmHg), presence of orthostatic hypotension, renin and aldosterone levels and ratio (ng/L and pmol/L respectively), natremia (mmol/L), natriuresis (mmol/d), kalemia (mmol/L), kaliuresis (mmol/d), chloremia (mmol/L), bicarbonatemia (mmol/L), brain natriuretic peptid (ng/L), hemoglobin (g/L) and sodium intake estimated by the dietician and calculated thanks to natriuresis (g/d)
|
1 month after initiation of KAFTRIO
|
|
Change in volemic parameter
Time Frame: 7 month after initiation of KAFTRIO
|
body mass index (BMI) (kg/m²), systolic and diastolic blood pressure (mmHg), presence of orthostatic hypotension, renin and aldosterone levels and ratio (ng/L and pmol/L respectively), natremia (mmol/L), natriuresis (mmol/d), kalemia (mmol/L), kaliuresis (mmol/d), chloremia (mmol/L), bicarbonatemia (mmol/L), brain natriuretic peptid (ng/L), hemoglobin (g/L) and sodium intake estimated by the dietician and calculated thanks to natriuresis (g/d)
|
7 month after initiation of KAFTRIO
|
|
Change in renal function
Time Frame: 1 month after initiation of KAFTRIO
|
(measured using creatinine (µmol/L) and cystatin C (mg/L)combined to report 2021 CKD-EPIcreatinineand CKD-EPIcreatinine-cystatin C formulas) and in plasma urea levels (mmol/L).
|
1 month after initiation of KAFTRIO
|
|
Change in renal function
Time Frame: 7 month after initiation of KAFTRIO
|
(measured using creatinine (µmol/L) and cystatin C (mg/L)combined to report 2021 CKD-EPIcreatinineand CKD-EPIcreatinine-cystatin C formulas) and in plasma urea levels (mmol/L).
|
7 month after initiation of KAFTRIO
|
|
Change in urinary sediment
Time Frame: 1 month after initiation of KAFTRIO
|
, represented by proteinuria (g/day), albuminuria/creatininuria ratio (mg/g) and urinary beta-2-microglobulin level (mg/day), after collecting 24-hours urine sa
|
1 month after initiation of KAFTRIO
|
|
Change in urinary sediment
Time Frame: 7 month after initiation of KAFTRIO
|
, represented by proteinuria (g/day), albuminuria/creatininuria ratio (mg/g) and urinary beta-2-microglobulin level (mg/day), after collecting 24-hours urine sa
|
7 month after initiation of KAFTRIO
|
|
Change in glycemic profile
Time Frame: 1 month after initiation of KAFTRIO
|
(fasting blood glucose level (mmol/L) and glycated hemoglobin (%)) and nutritional profile (albumin and pre-albumin in g/L).
|
1 month after initiation of KAFTRIO
|
|
Change in glycemic profile
Time Frame: 7 month after initiation of KAFTRIO
|
(fasting blood glucose level (mmol/L) and glycated hemoglobin (%)) and nutritional profile (albumin and pre-albumin in g/L).
|
7 month after initiation of KAFTRIO
|
|
Change in lung function
Time Frame: 1 month after initiation of KAFTRIO
|
predicted forced expiratory volume in 1 second (FEV1) (%) and peak expiratory flow (%)).
|
1 month after initiation of KAFTRIO
|
|
Change in lung function
Time Frame: 7 month after initiation of KAFTRIO
|
predicted forced expiratory volume in 1 second (FEV1) (%) and peak expiratory flow (%)).
|
7 month after initiation of KAFTRIO
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Etienne NOVEL-CATIN, MD, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 22-5080
- 69HCL23_1169 (Other Identifier: Easydore)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.